Welcome back to Markets Desk, here's what's moving the conversation this afternoon.
The Federal Reserve's next chapter may already be written. Treasury Secretary Scott Bessent has floated the idea of a single rate hike under a potential Kevin Warsh Fed, what he called a tap the brakes move. Analysts are reading that as a White House signal that tighter policy could return sooner than markets have priced in, and bond traders are paying close attention.
Shifting to earnings country, Netflix is delivering the growth but the stock is heading the other direction. The concern driving the selloff isn't the fundamentals — it's the deal speculation. Analysts say investors are worried the streaming giant is feeling pressure to make a splashy acquisition, and that kind of M and A anxiety tends to reprice a premium stock quickly and painfully.
And in the pharmaceutical space, AbbVie is making an eleven billion dollar bet on immunology, a megadeal that signals the drugmaker is serious about life after Humira. With patent cliffs reshaping the entire sector, AbbVie is essentially buying its next decade of revenue, and the market will be watching closely to see whether the science justifies the price tag.
That's the tape. Markets Desk, signing off the floor.
